
|Videos|November 4, 2015
How Have High Cost Hepatitis C Drugs Impacted Specialty Pharmacy?
Author(s)Davy James, Managing Editor
Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.
Advertisement
Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
2
New CKD Outcome Set Tells Pharmacists What to Measure
3
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
4
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
5


































































































